Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

M D Anderson Cancer Center

Houston, Texas, 77030, United States

About this study

Primary Objective:

To determine the feasibility and turnaround of clinical WES and transcriptome sequencing

Secondary Objectives:

To determine the frequency of actionable DNA and RNA alterations
To determine the concordance of DNA and RNA alterations
To determine the frequency of molecularly matched therapy
To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
To determine the feasibility of molecularly matched therapy to acquired resistance alterations

Exploratory Objectives:

To determine the feasibility of prioritizing targets with precision analytics
To determine clinical outcomes in patients receiving molecularly matched therapy
To determine the role of additional emerging diagnostic technologies

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patient Eligibility:

Inclusion criteria

Male/female patients who are at least 18 years of age on the day of informed consent signing.
Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
Provision of written informed consent for the study.

Exclusion criteria

None

Treatment and study plan

Molecular Functional Portrait

Other

Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test

Primary outcomes

Percentage of participants who have genomic test results available in <=7 days

Time frame: through study completion an average of 1 year

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2027
Study completion: 2027
First posted: Jul 19, 2022
Registry last updated: Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting